Charles River Laboratories Intl. (CRL) Given a $123.00 Price Target by Robert W. Baird Analysts

Charles River Laboratories Intl. (NYSE:CRL) has been given a $123.00 price objective by research analysts at Robert W. Baird in a research note issued on Tuesday. The firm presently has a “buy” rating on the medical research company’s stock. Robert W. Baird’s price target would suggest a potential upside of 14.25% from the company’s current price.

Several other research analysts also recently commented on CRL. Credit Suisse Group reaffirmed a “neutral” rating and issued a $112.00 price target (up previously from $95.00) on shares of Charles River Laboratories Intl. in a research note on Monday, October 16th. Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research note on Tuesday, October 24th. Bank of America reduced their price target on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $113.00 price target on shares of Charles River Laboratories Intl. in a research note on Friday, November 17th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Charles River Laboratories Intl. has an average rating of “Buy” and an average target price of $113.08.

Charles River Laboratories Intl. (NYSE:CRL) opened at $107.66 on Tuesday. The company has a market cap of $4,830.40, a PE ratio of 26.26, a P/E/G ratio of 1.50 and a beta of 0.74. Charles River Laboratories Intl. has a 12 month low of $85.00 and a 12 month high of $119.05. The company has a quick ratio of 1.62, a current ratio of 1.88 and a debt-to-equity ratio of 1.13.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.25 by $0.15. The company had revenue of $478.50 million for the quarter, compared to the consensus estimate of $475.02 million. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. The firm’s revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.21 EPS. analysts forecast that Charles River Laboratories Intl. will post 5.14 earnings per share for the current fiscal year.

In other Charles River Laboratories Intl. news, Director Online Communications Bdirect sold 131,000 shares of the stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $0.29, for a total transaction of $37,990.00. Also, Director C Richard Reese sold 10,227 shares of the stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total transaction of $1,047,244.80. Following the transaction, the director now owns 51,444 shares in the company, valued at $5,267,865.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 195,673 shares of company stock worth $2,644,046. 2.20% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its holdings in shares of Charles River Laboratories Intl. by 1,071.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,054 shares of the medical research company’s stock valued at $115,000 after buying an additional 964 shares in the last quarter. YorkBridge Wealth Partners LLC boosted its holdings in shares of Charles River Laboratories Intl. by 445.5% in the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after buying an additional 891 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Charles River Laboratories Intl. by 69.0% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after buying an additional 548 shares in the last quarter. Advisor Group Inc. boosted its holdings in shares of Charles River Laboratories Intl. by 159.4% in the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after buying an additional 945 shares in the last quarter. Finally, Zions Bancorporation bought a new stake in shares of Charles River Laboratories Intl. in the 3rd quarter valued at about $212,000. Institutional investors own 97.13% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/13/charles-river-laboratories-intl-s-crl-buy-rating-reaffirmed-at-robert-w-baird.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply